PFG Investments LLC Has $985,000 Holdings in Aldeyra Therapeutics, Inc. $ALDX

Key Points

• PFG Investments LLC significantly increased its stake in Aldeyra Therapeutics by 397.2% during the second quarter, now holding 257,300 shares worth approximately $985,000.
• Aldeyra Therapeutics recently reported a quarterly earnings per share (EPS) of (-$0.16), exceeding expectations by $0.05, while analysts forecast an EPS of (-$0.92) for the current fiscal year.
• The stock currently has a consensus rating of "Moderate Buy" with an average price target set at $9.50, following recent upgrades from several analysts.

PFG Investments LLC boosted its position in shares of Aldeyra Therapeutics, Inc. (NASDAQ:ALDX - Free Report) by 397.2% during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 257,300 shares of the biotechnology company's stock after buying an additional 205,550 shares during the period. PFG Investments LLC owned approximately 0.43% of Aldeyra Therapeutics worth $985,000 at the end of the most recent quarter.

Other hedge funds have also recently bought and sold shares of the company. Public Employees Retirement System of Ohio bought a new stake in shares of Aldeyra Therapeutics during the 2nd quarter worth approximately $25,000. Inspirion Wealth Advisors LLC bought a new stake in Aldeyra Therapeutics during the second quarter worth $38,000. Capital Advisors Wealth Management LLC acquired a new stake in shares of Aldeyra Therapeutics in the 1st quarter valued at $62,000. Wealth Enhancement Advisory Services LLC bought a new position in shares of Aldeyra Therapeutics in the 1st quarter valued at $63,000. Finally, Pallas Capital Advisors LLC bought a new position in shares of Aldeyra Therapeutics in the 2nd quarter valued at $68,000. 59.71% of the stock is owned by institutional investors.

Aldeyra Therapeutics Trading Up 1.5%

Aldeyra Therapeutics stock opened at $5.32 on Friday. The stock has a 50-day moving average price of $5.36 and a two-hundred day moving average price of $4.08. Aldeyra Therapeutics, Inc. has a 12 month low of $1.14 and a 12 month high of $7.20. The company has a market capitalization of $318.65 million, a PE ratio of -6.26 and a beta of 0.83.

Aldeyra Therapeutics (NASDAQ:ALDX - Get Free Report) last released its quarterly earnings data on Thursday, August 7th. The biotechnology company reported ($0.16) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.21) by $0.05. As a group, analysts predict that Aldeyra Therapeutics, Inc. will post -0.92 earnings per share for the current fiscal year.

Insider Transactions at Aldeyra Therapeutics

In other news, insider Stephen Machatha sold 22,073 shares of the firm's stock in a transaction on Monday, August 11th. The shares were sold at an average price of $5.15, for a total transaction of $113,675.95. Following the completion of the transaction, the insider owned 221,799 shares of the company's stock, valued at approximately $1,142,264.85. This trade represents a 9.05% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 9.60% of the company's stock.

Analysts Set New Price Targets

Several analysts recently weighed in on the company. Zacks Research raised Aldeyra Therapeutics to a "hold" rating in a research note on Friday, August 8th. Wall Street Zen upgraded shares of Aldeyra Therapeutics from a "sell" rating to a "hold" rating in a research note on Saturday, June 21st. Two investment analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company's stock. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $9.50.

About Aldeyra Therapeutics

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company's lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.